Morning Buzz: China Finance Online (JRJC), Array BioPharma Inc. (ARRY), Amgen (AMGN, Valeant (VRX)

Shares of China Finance Online Co., Ltd. (JRJC) are higher by nearly 38% to $6.28 in pre-market trading on Wednesday after the Chinese web-based financial services firm reported third-quarter unaudited financial results. The micro cap saw its net revenue come in at $37 million, up 74.8% year-over-year. Net income was $9.7 million, substantially above last year’s $2.4 million.

Array BioPharma Inc. (ARRY) shares surged 26.63% to $4.85 in pre-market trading after the company reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial.

“We are excited to announce positive results from the NEMO trial, which suggest binimetinib has the potential to provide an important new treatment option for patients with advanced NRAS melanoma,” said Ron Squarer, Chief Executive Officer, Array BioPharma. “We look forward to discussing the data with the FDA and other regulatory agencies in the near future.”

Amgen Inc (AMGN) — The biotech increased its quarterly dividend by 27% to $1 per share. The new $1/shr dividend will be paid March 8, 2016, to shareholders of record as of Feb. 16.

Shares of Valeant Pharmaceuticals International, Inc. (VRX) were up 3.48% in pre-market hours despite the Canadian drug maker cutting its Q4 earnings outlook.

The company said Q4 adjusted EPS are projected to come in at $2.55 to $2.65, compared to previous estimates of $4.00 to $4.20. Total revs previously $3.25 – $3.45 billion now $2.7 – $2.8 billion.

Valeant also provided a 2015 outlook below current consensus estimates ahead of its Investor Day. Adjusted EPS previously $11.67 – $11.87 now $10.23 – $10.33. Total revenue previously $11.0 – $11.2 billion now $10.4 -$10.5 billion.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.